SG Americas Securities LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

SG Americas Securities LLC lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 76.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,390 shares of the biopharmaceutical company’s stock after selling 10,717 shares during the quarter. SG Americas Securities LLC’s holdings in Alnylam Pharmaceuticals were worth $932,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at $26,000. Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $30,000. V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $52,000. Finally, Meeder Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 1,237.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 297 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $284.32 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The stock has a market cap of $36.50 billion, a P/E ratio of -473.86 and a beta of 0.39. The stock has a 50-day simple moving average of $269.10 and a 200-day simple moving average of $211.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. During the same period last year, the company earned ($2.21) earnings per share. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ALNY. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $198.00 to $370.00 in a report on Friday, August 16th. Barclays raised their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday. Finally, Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $285.62.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company’s stock, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,398 shares of company stock worth $13,595,460 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.